SEARCH

SEARCH BY CITATION

References

  • 1
    van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 2
    Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94: 19148.
  • 3
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 247983.
  • 4
    Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008 (Jan 1); 14 (1): 16977.
  • 5
    Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 183847.
  • 6
    Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009; 15: 108695.
  • 7
    Leffers N, Vermeij R, Hoogeboom BN et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012 (Jan 1); 130 (1): 10512. doi:10.1002/ijc.25980.
  • 8
    Kakimi K, Isobe M, Uenaka A et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 2011; 129: 283646.
  • 9
    Barve M, Bender J, Senzer N et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008; 26: 441825.
  • 10
    Chianese-Bullock KA, Irvin WP Jr, Petroni GR et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31: 42030.
  • 11
    Slingluff CL Jr, Petroni GR, Olson WC et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15: 703644.
  • 12
    Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69: 91727.
  • 13
    Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 1719.
  • 14
    Krug LM, Dao T, Brown AB et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59: 146779.
  • 15
    Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother 2011; 60: 16171.
  • 16
    Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29: 292432.
  • 17
    Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 (Jul 29). doi: 10.1038/nm.2883. [Epub ahead of print].
  • 18
    Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1 : 75161.
  • 19
    Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13 : 638695.
  • 20
    Meyer RG, Korn S, Micke P et al. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 2007; 58(1): 8894.
  • 21
    Morse MA, Secord AA, Blackwell K et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17: 340819.
  • 22
    Holmes JP, Benavides LC, Gates JD et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26: 342633.
  • 23
    Perez SA, Kallinteris NL, Bisias S et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010; 16: 3495506.
  • 24
    Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006; 6: 131121.
  • 25
    Takahashi N, Ohkuri T, Homma S et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012 (Jan); 103 (1): 1503. doi:10.1111/j.1349-7006.2011.02106.x.
  • 26
    Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 9706.
  • 27
    Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39: 7380.
  • 28
    Tanaka S, Harada M, Mine T et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 2003; 26: 357366.
  • 29
    Mine T, Gouhara R, Hida N et al. Immunological evaluation of CTL precusor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 548556.
  • 30
    Sato Y, Shomura H, Maeda Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003; 94: 802808.
  • 31
    Noguchi M, Kobayashi K, Suetsugu N et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003; 57: 8092.
  • 32
    Noguchi M, Itoh K, Suekane S et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004; 60: 3245.
  • 33
    Noguchi M, Itoh K, Suekane S et al. Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 2004; 95: 7784.
  • 34
    Sato Y, Maeda Y, Shomura H et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90: 1333413342.
  • 35
    Tsuda N, Mochizuki K, Harada M et al. Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 6067.
  • 36
    Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11: 59005911.
  • 37
    Noguchi M, Itoh K, Yao A et al. Immunological evaluation of individualized peptide vaccination with a low-dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 112.
  • 38
    Noguchi M, Mine T, Yamada A et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 2007; 16: 341349.
  • 39
    Noguchi M, Yao A, Harada M et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007; 67: 933942.
  • 40
    Sato Y, Fujiwara T, Mine T et al. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007; 98: 11131119.
  • 41
    Yanagimoto H, Mine T, Yamamoto K et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007; 98: 605611.
  • 42
    Yoshiyama K, Terazaki Y, Matsueda S et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 2012; 40: 1492500.
  • 43
    Suekane S, Nishitani M, Noguchi M et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer 2007; 98: 19651968.
  • 44
    Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 10011009.
  • 45
    Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795801.
  • 46
    Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 2011; 71: 470479.
  • 47
    Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 337344.
  • 48
    Matsumoto K, Noguchi M, Satoh T et al. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int 2011; 108: 8318.
  • 49
    Noguchi M, Moriya F, Suekane S et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 2012; 72: 83445.
  • 50
    Terazaki Y, Yoshiyama K, Matsueda S et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 2012; 103: 63844.
  • 51
    Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007; 56: 148599.
  • 52
    Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 76272.
  • 53
    Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29: 3306.
  • 54
    Rahma OE, Ashtar E, Czystowska M et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61: 37384.
  • 55
    Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 71123. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010;363(13):1290.
  • 56
    Yuan J, Ginsberg B, Page D et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011; 60: 113746.
  • 57
    Sarnaik AA, Yu B, Yu D et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011; 17: 896906.